Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|October 26, 2015
Instrument Integration for Dissolution Testing
Author(s)Pharmaceutical Technology Editors
Shimadzu and Hanson Research partner on pharmaceutical testing instrument integration.
Shimadzu and Hanson Research have announced a strategic partnership to integrate Hanson’s semi-automated Vision dissolution platform with Shimadzu’s UV-1800 to create an automated on-line system designed to meet demand for automation efficiencies, better reporting and data integrity, audit-proof security compliance, and simplification of complex processes.
In addition, Hanson will introduce a semi-automated integration of the company's Vision AutoPlus dissolution autosampler to Shimadzu’s HPLC product for dissolution labs that require an HPLC analytical finish.
The Shimadzu and Hanson-integrated products were launched at the American Association of Pharmaceutical Scientists (AAPS) annual meeting and expo in Orlando, FL.
Source:
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.